Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
FDA Accepts NDA for Insomnia Med Lemborexant, Target Date Set for Dec. 27
Eisai and its US partner Imbrium Therapeutics said on March 12 that the US FDA has accepted a new drug application for their insomnia treatment lemborexant, with the target action date under the Prescription Drug User Fee Act (PDUFA) set…
To read the full story
Related Article
- Eisai’s Insomnia Med Dayvigo Now Available in US
June 3, 2020
- Eisai’s Insomnia Drug Grabs US Approval, Japan Nod Expected Soon
December 24, 2019
- Eisai Seeks Japan Approval for Insomnia Med Lemborexant
March 8, 2019
- Insomnia Treatment Lemborexant Filed for US Approval: Eisai, Purdue Pharma
January 16, 2019
- Eisai’s Insomnia Treatment Lemborexant Smashes Primary Target in Long-Term PIII Study
October 18, 2018
BUSINESS
- Leqembi Iqlik Now Available for Alzheimer’s Initiation Use in US
August 25, 2026
- FDA Puts Regenxbio’s MPS II Gene Therapy Back on Clinical Hold
August 25, 2026
- Toho Builds Alternative Drug Delivery Options for Disaster Readiness
August 25, 2026
- OB/GYN Sees Abrysvo Becoming Part of Prenatal Care as NIP Drives Uptake
August 25, 2026
- Daiichi Sankyo Taps Ken Keller as New Commercial Chief in Global Revamp
August 25, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…